There has been international debate on the infrequent occurrence of malignant hyperthermia in infants, where some reports state that this phenomenon does not exist in this age group; but the vast majority of studies counteract this argument. The proportion of documented cases in the infant population warrants a good review of cases and description of symptomatology observed with malignant hyperthermia in this cohort. It is paramount for clinicians of the pediatric population to recognize patients at risk of having a crisis, and to communicate this concern to the surgical/anesthetic team and also to be cognizant of the level of care necessary following a crisis.
ChamleyDPollockNAStowellKMBrownRL. Malignant hyperthermia in infancy and identification of novel RYR1 mutation. Br J Anaesthesia. 2000;84:500-504.
2.
WedelDJ. Malignant hyperthermia—prevention and treatment. ASA Newslett. 1997;61(4):13-15.
3.
PluradDBlaschkeGJonesSPfeifferJ. A case of malignant hyperthermia in a child encountered during a humanitarian assistance mission to the Philippines. Mil Med. 2008;173:805-808.
4.
HalsallPJCainePAEllisFR. Retrospective analysis of anesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized. Br J Anaesth. 1979;51:949-954.
5.
European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia susceptibility. Br J Anaesth. 1984;56:1267-1269.
6.
GirardTJöhrMSchaeferCUrwylerA. Perinatal diagnosis of malignant hyperthermia susceptibility. Anesthesiology. 2006;104:1353-1354.
7.
WilhoitRBrownRBaumanL. Possible malignant hyperthermia in a 7 week old infant. Anesth Analg. 1989;68:688-691.
8.
WiswellTEBentRCSolenbergerR. Malignant hyperthermia in infancy. South Med J. 1989;82:1451-1452.
9.
D FranklinALorincANDonahueBS. Malignant hyperthermia-like manifestations in a two-month-old child with Holt-Oram syndrome undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 2014;28:1326-1327.
10.
WitherspoonK. ECMO for resuscitation of an infant immediately post op VSD closure and RVOT repair: a case report of possible malignant hyperthermia. Prog Pediatr Cardiol. 2008;24:131-135.
11.
BaileyAGBlochEC. Malignant hyperthermia in a three-month-old American Indian infant. Anesth Analg. 1987;66:1043-1045.
LarachMGBrandonBWAllenGCGronertGALehmanEB. Cardiac arrests and deaths associated with malignant hyperthermia in north America from 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia association of the United States. Anesthesiology. 2008;108:603-611.
14.
WedelDJ. The effect of age on the development of MH in susceptible piglets. Anesthesiology. 1994;81:A426.
15.
LitmanRSRosenbergH. Malignant hyperthermia: update on susceptibility testing. JAMA. 2005;293:2918-2924.
DeufelTGollaAIlesD. Evidence for genetic heterogeneity of malignant hyperthermia susceptibility. Am J Hum Genet. 1992;50:1151-1161.
18.
MacLennanDHDuffCZorzatoF. Ryanoding receptor gene is a candidate for predisposition to malignant hyperthermia. Nature. 1990;343:559-561.
19.
McCarthyTVHealyJMHeffronJJ. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature. 1990;343:562-564.
20.
LevittRCOlckersAMeyersS. Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. Genomics. 1992;14:562-566.
21.
OlckersAMeyersDAMeyersS. Adult muscle sodium channel alpha subunit is a gene candidate for malignant hyperthermia susceptibility. Genomics. 1992;14:829-831.
22.
IIesDELehmann-HornFSchererSW. Localization of the gene encoding the α2/δ subunits of the L-type voltage dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet. 1994;3:969-975.
23.
SudbrakRProcaccioVKlausnitzerM. Mapping of a further malignant hyperthermia susceptible locus to chromosome 3q13.1. Am J Hum Genet. 1995;56:684-691.
24.
MonnierNProcaccioVStieglitzPLunardiJ. Malignant hyperthermia susceptibility is associated with a mutation of the alpha-1 subunit of the human dihydropyridine-sensitive L type voltage dependent calcium channel receptor in skeletal muscle. Am J Hum Genet. 1997;60:1316-1325.
25.
StewartSLHorganKRosenbergHFletcherJE. Identification of the Arg1086His mutation in the alpha subunit of the voltage dependent calcium channel (CACNA 1S) in a North American family with malignant hyperthermia. Clin Genet. 2001;59:178-184.
26.
RobinsonRLMonnierNWolzW. A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees. Hum Mol Genet. 1997;6:953-961.
27.
RobinsonRLCurranJLHallWJ. Genetic heterogeneity and HOMOG analysis in British malignant hyperthermia families. J Med Genet. 1998;35:196-201.
28.
DeufelTSudbrakRFeistY. Discordance in a malignant hyperthermia pedigree, between the in vitro contracture test phenotypes and haplotypes for the MHS1 region of chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene. Am J Hum Genet. 1995;56:1332-1342.
29.
FagerlundTHOrdingHBendixenDIslanerGRanklev TwetmanEBergK. Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutation. Clin Genet. 1997;52:416-421.
30.
AdeokunAMWestSPEllisFRThe G1021A substitution in the RYR1 gene does not cosegregate with malignant hyperthermia in a British pedigree. Am J Hum Genet. 1997;60:833-841.
31.
FaustDKGergisSDSokollMD. Management of suspected malignant hyperpyrexia in an infant. Anesth Analg. 1979;58:33-35.
32.
LarachMGBrandomBWAllenGCGronertGALehmanEB. Cardiac arrests and deaths associated with malignant hyperthermia in North America from 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Anesthesiology. 2008;108:603-611.
33.
NelsonPLitmanRS. Malignant hyperthermia in children: an analysis of the North American Malignant Hyperthermia Registry. Anesth Analg. 2014;118:369-374.
